
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


IQVIA Holdings Inc (IQV)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: IQV (2-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $215.05
1 Year Target Price $215.05
14 | Strong Buy |
2 | Buy |
7 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 26.04% | Avg. Invested days 43 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 32.44B USD | Price to earnings Ratio 27.61 | 1Y Target Price 215.05 |
Price to earnings Ratio 27.61 | 1Y Target Price 215.05 | ||
Volume (30-day avg) 23 | Beta 1.3 | 52 Weeks Range 134.65 - 252.69 | Updated Date 08/29/2025 |
52 Weeks Range 134.65 - 252.69 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 6.91 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 7.88% | Operating Margin (TTM) 13.39% |
Management Effectiveness
Return on Assets (TTM) 5.16% | Return on Equity (TTM) 19.79% |
Valuation
Trailing PE 27.61 | Forward PE 16 | Enterprise Value 45596100000 | Price to Sales(TTM) 2.07 |
Enterprise Value 45596100000 | Price to Sales(TTM) 2.07 | ||
Enterprise Value to Revenue 2.9 | Enterprise Value to EBITDA 13.61 | Shares Outstanding 170000000 | Shares Floating 161462600 |
Shares Outstanding 170000000 | Shares Floating 161462600 | ||
Percent Insiders 1.05 | Percent Institutions 102.09 |
Upturn AI SWOT
IQVIA Holdings Inc

Company Overview
History and Background
IQVIA Holdings Inc. was formed in 2017 through the merger of IMS Health and Quintiles. IMS Health, founded in 1954, focused on healthcare data and analytics. Quintiles, established in 1982, was a leading contract research organization (CRO). The merger created a comprehensive provider of biopharmaceutical development and commercial outsourcing services.
Core Business Areas
- Technology & Analytics Solutions (TAS): Provides data, analytics, and technology solutions to healthcare clients, including pharmaceutical companies, healthcare providers, and payers. This includes real-world data, market research, and software platforms.
- Research & Development Solutions (RDS): Offers contract research organization (CRO) services, supporting biopharmaceutical companies in clinical trials and drug development. This includes clinical trial management, data management, and regulatory consulting.
Leadership and Structure
Ari Bousbib is the Chairman and CEO. The organizational structure includes various business units and functional departments reporting to the CEO, with a board of directors providing oversight.
Top Products and Market Share
Key Offerings
- IQVIA CORE: A suite of data, analytics, and technology solutions that provide insights into healthcare trends, patient behavior, and market dynamics. Estimated market share within healthcare data and analytics is approximately 25%. Key competitors include Veeva Systems (VEEV), Oracle Cerner (ORCL), and Accenture (ACN).
- Clinical Trial Management Services: Provides comprehensive clinical trial management services, including protocol development, site selection, patient recruitment, and data management. Holds a significant share of the CRO market, competing with Labcorp (LH), Thermo Fisher Scientific (TMO), and Charles River Laboratories (CRL).
Market Dynamics
Industry Overview
The healthcare industry is undergoing significant transformation, driven by factors such as increasing healthcare costs, aging populations, and technological advancements. There is a growing demand for data-driven insights and outsourcing solutions.
Positioning
IQVIA is a leading player in the healthcare intelligence and clinical research space. Its competitive advantages include its comprehensive data assets, global reach, and integrated service offerings.
Total Addressable Market (TAM)
The TAM for healthcare technology and CRO services is estimated to be over $200 billion. IQVIA is well-positioned to capture a significant share of this market due to its broad portfolio and established relationships.
Upturn SWOT Analysis
Strengths
- Extensive data assets
- Global reach
- Integrated service offerings
- Strong brand reputation
- Experienced management team
Weaknesses
- High debt levels
- Integration risks from acquisitions
- Dependence on pharmaceutical industry
- Potential for data privacy breaches
- Complex organizational structure
Opportunities
- Growing demand for healthcare data and analytics
- Expanding CRO market
- Increasing adoption of technology in healthcare
- Opportunities in emerging markets
- Potential for strategic partnerships
Threats
- Intense competition
- Regulatory changes
- Economic downturn
- Data privacy and security concerns
- Technological disruption
Competitors and Market Share
Key Competitors
- VEEV
- LH
- TMO
- ACN
- ORCL
Competitive Landscape
IQVIA holds a strong position due to its comprehensive data assets and integrated service offerings, but faces competition from specialized players like Veeva in software and larger CROs like Labcorp.
Major Acquisitions
Deep Current
- Year: 2021
- Acquisition Price (USD millions): 0
- Strategic Rationale: Enhance patient data and real world insights into US healthcare
ADVANZ Pharma's Global Generics Business
- Year: 2020
- Acquisition Price (USD millions): 0
- Strategic Rationale: Gain access to broader product portfolio to provide services.
Growth Trajectory and Initiatives
Historical Growth: IQVIA has experienced steady growth in recent years, driven by organic growth and acquisitions.
Future Projections: Analysts project continued growth for IQVIA, driven by demand for its data and analytics solutions and CRO services.
Recent Initiatives: IQVIA has been focused on expanding its data assets, investing in technology, and entering new markets.
Summary
IQVIA is a strong company with a leading position in the healthcare intelligence and clinical research space. Its comprehensive data assets and integrated service offerings provide a competitive advantage. However, high debt levels and reliance on the pharmaceutical industry pose potential risks. Expansion in emerging markets and strategic partnerships offer opportunities for future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (10-K, 10-Q)
- Market Research Reports
- Analyst Reports
- Company Website
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About IQVIA Holdings Inc
Exchange NYSE | Headquaters Durham, NC, United States | ||
IPO Launch date 2013-05-09 | CEO & Chairman Mr. Ari Bousbib | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 90000 | Website https://www.iqvia.com |
Full time employees 90000 | Website https://www.iqvia.com |
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. It has a strategic collaboration with Sarah Cannon Research Institute to enhance clinical trial processes. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is based in Durham, North Carolina.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.